It would be interesting to evaluate whether CDK6 inhibitors can cooperate with TKIs in inducing a more profound clearance of leukemic cells and possibly increasing the likelihood of achieving MRD-negative status, which is a powerful predictor of response to therapy in ALL [42,134]. The gene discussed is CDK6; the disease is acute lymphoblastic leukemia.